Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

149.65 -0.20 (-0.13%)
Streaming Delayed Price Updated: 10:48 AM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Johnson & Johnson to Participate in the SVB Securities Global Biopharma Conference
From Johnson & Johnson
Via Business Wire
Drug Delivery Market – Major Technology Giants in Buzz Again : Johnson & Johnson, Sanofi, Pfizer
How to reach that market place and its associated audience with current marketing efforts? Benchmark now the competitive efforts with high growth emerging players and leaders of Drug Delivery Market. 
Via SBWire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
Exposures US Equities
3 Dividend Stocks For Passive Income
I'm aiming to grow my passive income this year through adding these safe value stocks to my portfolio that have strong dividend yields. 
Via MarketBeat
Topics Economy
Exposures Economy
Financial Resources Federal Credit Union Taps Scienaptic's Platform to Power its Credit Decisions With AI
NEW YORK - Jan. 11, 2023 - PRLog -- Leading global AI-powered credit decision platform provider, Scienaptic AI, announced today that Financial Resources Federal Credit Union has chosen to implement its... 
Via PRLog
Topics Artificial Intelligence
Exposures Artificial Intelligence
These Steelmakers Deserve A Place On Your 2023 Watch List
Steel stocks including Nucor and Steel Dynamics are bringing holiday cheer to investors as they have potential to benefit from infrastructure spending in 2023. 
Via MarketBeat
Johnson & Johnson Completes Acquisition of Abiomed
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
Two Blue Chip Health Companies The Institutions Are Buying
Johnson & Johnson and Abbott Laboratories are two Dividend Kings the analysts are buying, one stock is ready to rebound and the other to lead the market. 
Via MarketBeat
MarketBeat: Week in Review 12/05 – 12/09
The markets continue to have a lot to digest before there can be a Santa Claus raly. Here are some of the top stories our analysts were covering this week. 
Via MarketBeat
Topics Economy Electric Vehicles Supply Chain
Exposures Electric Vehicles Interest Rates Supply Chain
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. 
Via MarketBeat
Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Johnson & Johnson
Via Business Wire
Baby Needs Market to Eyewitness Massive Growth by 2027 : Johnson & Johnson, Kimberly Clark, Procter & Gamble
Stay up-to-date with Baby Needs Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board
From Johnson & Johnson
Via Business Wire
Four Healthcare Stocks To Watch This Week
Healthcare has long been a wise investment, as the industry consistently grows yearly. Some analysts believe that trend will continue. 
Via MarketBeat
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Healthcare and Medical Leaders Gather to Shape the Future of Global Health
Via ACN Newswire
Topics Economy
Exposures Economy
Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
Learn more about Organicell Regenerative Medicine, Inc.from this latest report. 
Via TheNewswire.com
Exposures COVID-19 Product Safety
Spotlight on Healthcare Collaboration and Innovation at Asia Summit on Global Health and HK International Medical and Healthcare Fair
Via ACN Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
From Brodsky & Smith LLC
Via GlobeNewswire
Blue Chip Stocks and Dividend Yields
How to invest in blue chip stocks, exactly? The short answer: carefully, just like with any other investment. Investing in blue-chip stocks depends on your preferences, risk tolerance, portfolio... 
Via MarketBeat
Johnson & Johnson (NYSE: JNJ) Set to Acquire Abiomed (NASDAQ: ABMD) for $16.6 Billion or $380 per Share Plus CVR
Abiomed, Inc. (NASDAQ: ABMD) is engaged as a medical technology company, which is focused on providing support and resources to 
Via Spotlight Growth
Exposures Product Safety
Johnson & Johnson to Acquire Abiomed
From Johnson & Johnson
Via Business Wire
Inaugural International Healthcare Week promotes Hong Kong as leading healthcare hub
Via ACN Newswire
Exposures COVID-19
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all... 
Via MarketBeat
MarketBeat: Week in Review 10/17-10/21
Stocks are staging a rally to end the week. But economic data next week may bring more volatility. Here are some of the most popular articles from this week 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
JNJ stock is seen as a defensive play which has typically done well in bear markets. But there is one issue that makes longer-term forecasts uncertain 
Via MarketBeat
Topics Economy
Exposures Economy
Johnson & Johnson Reports Q3 2022 Results
From Johnson & Johnson
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.